Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Depreciation and Depletion: 2022-2024

Historic Depreciation and Depletion for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $48,000.

  • Centessa Pharmaceuticals' Depreciation and Depletion fell 47.83% to $48,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $300,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $300,000 for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q4 2024, Centessa Pharmaceuticals' Depreciation and Depletion stood at $48,000, which was down 41.46% from $82,000 recorded in Q3 2024.
  • Centessa Pharmaceuticals' 5-year Depreciation and Depletion high stood at $92,000 for Q4 2023, and its period low was $28,000 during Q1 2022.
  • Its 3-year average for Depreciation and Depletion is $60,917, with a median of $65,000 in 2024.
  • In the last 5 years, Centessa Pharmaceuticals' Depreciation and Depletion spiked by 162.50% in 2023 and then crashed by 47.83% in 2024.
  • Centessa Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $36,000 in 2022, then surged by 155.56% to $92,000 in 2023, then crashed by 47.83% to $48,000 in 2024.
  • Its last three reported values are $48,000 in Q4 2024, $82,000 for Q3 2024, and $84,000 during Q2 2024.